Retatrutide ReportClinical & Regulatory Intelligence

Comparisons

How Retatrutide Compares

Structured reference comparisons across the leading obesity and metabolic candidates, with the methodological caveats stated up front.

Competitive Landscape

Head-to-head reference cards

Side-by-side reference notes on mechanism, development stage and reported efficacy across leading candidates.

Cross-trial comparisons should be interpreted cautiously because study populations, trial designs, treatment durations and endpoints may differ.

Retatrutide vs Tirzepatide

Full comparison
Developer
Eli Lilly and CompanyEli Lilly and Company
Mechanism
GLP-1 / GIP / Glucagon triple agonistGLP-1 / GIP dual agonist
Administration
Once-weekly subcutaneousOnce-weekly subcutaneous
Development Stage
Phase 3Approved (obesity, type 2 diabetes)
Trial Population
Obesity ± type 2 diabetesObesity, type 2 diabetes, OSA
Efficacy Data
≈-24% at 48 weeks (Phase 2)≈-21% at 72 weeks (Phase 3)
Study Duration
48–72 weeks72 weeks
Regulatory Status
InvestigationalApproved

Retatrutide vs Semaglutide

Full comparison
Developer
Eli Lilly and CompanyNovo Nordisk
Mechanism
GLP-1 / GIP / Glucagon triple agonistGLP-1 receptor agonist
Administration
Once-weekly subcutaneousOnce-weekly subcutaneous or oral
Development Stage
Phase 3Approved (obesity, type 2 diabetes)
Trial Population
Obesity ± type 2 diabetesObesity, type 2 diabetes, CV risk
Efficacy Data
≈-24% at 48 weeks (Phase 2)≈-15% at 68 weeks (Phase 3)
Study Duration
48–72 weeks68 weeks
Regulatory Status
InvestigationalApproved

Retatrutide vs CagriSema

Full comparison
Developer
Eli Lilly and CompanyNovo Nordisk
Mechanism
GLP-1 / GIP / Glucagon triple agonistAmylin analogue + GLP-1 agonist
Administration
Once-weekly subcutaneousOnce-weekly subcutaneous
Development Stage
Phase 3Phase 3 / regulatory submission
Trial Population
Obesity ± type 2 diabetesObesity, type 2 diabetes
Efficacy Data
≈-24% at 48 weeks (Phase 2)≈-22% at 68 weeks (Phase 3)
Study Duration
48–72 weeks68 weeks
Regulatory Status
InvestigationalInvestigational

Retatrutide vs Amycretin

Full comparison
Developer
Eli Lilly and CompanyNovo Nordisk
Mechanism
GLP-1 / GIP / Glucagon triple agonistAmylin + GLP-1 receptor co-agonist
Administration
Once-weekly subcutaneousSubcutaneous or oral (in development)
Development Stage
Phase 3Phase 2
Trial Population
Obesity ± type 2 diabetesOverweight and obesity
Efficacy Data
≈-24% at 48 weeks (Phase 2)≈-22% at 36 weeks (early phase)
Study Duration
48–72 weeks12–36 weeks
Regulatory Status
InvestigationalInvestigational

Retatrutide vs MariTide

Full comparison
Developer
Eli Lilly and CompanyAmgen
Mechanism
GLP-1 / GIP / Glucagon triple agonistGIP receptor antagonist / GLP-1 agonist
Administration
Once-weekly subcutaneousMonthly or less frequent subcutaneous
Development Stage
Phase 3Phase 3
Trial Population
Obesity ± type 2 diabetesObesity, type 2 diabetes
Efficacy Data
≈-24% at 48 weeks (Phase 2)≈-20% at 52 weeks (Phase 2)
Study Duration
48–72 weeks52 weeks
Regulatory Status
InvestigationalInvestigational

Weekly Briefing

The Retatrutide Report

One concise briefing covering the most important retatrutide clinical trial, research and regulatory developments.

No promotional content. Unsubscribe at any time.